A new class of bronchodilator improves lung function in COPD: A trial with GSK961081

This randomized, double-blind, placebo- and salmeterol-controlled, 28-day study evaluated the bronchodilator effects of GSK961081, administered using various doses and dosing schedules, in 436 patients with moderate-to-severe COPD. The primary endpoint was change in trough FEV1; secondary endpoints included the weighted mean for 0- to 24-hour serial FEV1 measurements in patients undergoing overnight spirometry, serial FEV1 on Day 28 up to 24 hours post-dose in the subgroup of patients undergoing overnight spirometry, and serial morning post-dose FEV1 0–12 hours on Days 1 and 28 in the overall cohort. Lung function testing was conducted using a Vitalograph spirometer.